GlobeNewswire Inc.··Inmune Bio Inc.INmune Bio Slashes Losses 44% in Q1 2026 While Advancing Alzheimer's Pipeline
INmune Bio reported Q1 2026 net loss of $5.4M, down from $9.7M year-ago. Company advancing XPro for Alzheimer's with $21.4M cash on hand.
INMBclinical trialsQ1 2026 earnings